Republicans have faced pushback for their plans to pay for Trump’s tax cuts by reducing federal Medicaid funding and by ...

A new agreement between the FDA and Avidity Biosciences could further assuage industry concerns about the agency’s stance on ...

Budget documents released Friday provide the first clear indication of the priorities of the proposed Administration for a ...

The Trump administration’s gutting of global aid is threatening to collapse a network of laboratories responsible for global ...

This is the online version of STAT’s weekly email newsletter Health Care Inc. Sign up here.

Metsera, the obesity-focused biotech, said this morning that its drug candidate targeting the amylin hormone showed marked ...

Several hundred NIH employees signed on to a letter rebuking agency actions since the start of President Trump's second term ...

Four termination notices and new federal documents. It was a busy weekend for a few STAT reporters. Yesterday, Helen Branswell reported this exclusive: Four out of 19 members of t ...

Fears about the FDA mposing steep barriers to gene therapies for rare diseases appeared moot at an agency roundtable ...

Metsera’s obesity drug candidate targeting the amylin hormone showed marked efficacy in an early trial, the company said ...

Companies like Sweetgreen, Daily Harvest, and Thrive Market have strong ties to MAHA leaders, including Casey and Calley ...

The Trump executive order is not a pathway to a “gold standard” — it is a blueprint for politicizing science and ...